Medtronic News

Medtronic Showcases Cardiovascular Devices at TCT 2010

Interventional Cardiology Meeting Features New Data on Resolute(R) Drug-Eluting Stent, IN.PACT(TM) Line of Drug-Eluting Balloons and CoreValve(R) Transcatheter Aortic Valve

MINNEAPOLIS, Sep 17, 2010 (BUSINESS WIRE) --

Representing the broadest range of medical technology for the interventional treatment of cardiovascular disease,Medtronic, Inc. (NYSE: MDT), today announced its schedule of events for Transcatheter Cardiovascular Therapeutics (TCT) 2010, which takes place Sept. 21-25 in Washington, D.C.

The conference will prominently feature new data on the Resolute drug-eluting stent (DES), including the primary endpoint of RESOLUTE International; the IN.PACT Falcon drug-eluting balloon; and the Medtronic CoreValve System. Highlights from Medtronic during TCT include:

Tuesday, September 21

- Drug-Eluting Stent Summit (Part 1): Appropriate Utilization of Current Generation Devices

  (Ballroom C)

  Session IV: Second and Third Generation Stents: Evidence for Improved Performance and Clinical Outcomes(Ballroom C)

  - 3:02 pm / Endeavor: Global clinical trial review and recommendations for use in 2010
  - 3:49 pm / Resolute: New insights from RESOLUTE All Comers
- Valvular Heart Disease Summit (Part 1): Overview and Aortic Valve Therapies

  Session VI, TAVI Part IV: Worldwide Clinical Outcomes (Room 151AB)

  - 1:34 pm / Echocardiographic and Angiographic Insights from the Two-Year Follow-up of the 18 Fr Medtronic CoreValve Safety and Efficacy Study
  - 1:42 pm / The Australia-New Zealand Medtronic CoreValve Registry: VARC-Adjudicated Outcomes in Inoperable and High Risk AS Patients
  - 2:00 pm / Updates from the ADVANCE and ADVANCE-2 Medtronic CoreValve Registries
  - 2:08 pm / SURTAVI: Design of a New Randomized Trial in Lower-Risk AS Patients
  - 2:16 pm / The Medtronic CoreValve US Pivotal Trial: Rationale, Goals, and Status Review
  - 2:24 pm / Expanding Aortic Valve Morphologies for Treatment with Medtronic CoreValve: Bicuspid Valves, Valve-in-Valve, and Aortic Regurgitation

  Session VIII, TAVI Part VI: New and Novel TAVI Systems(Room 151AB)

  - 5:30 pm / Progress with the Ventor Transapical TAVI System

Wednesday, September 22

- Drug-Eluting and Bare Metal Stent Studies I

  3:45 - 3:57 pm (Room 140A)

  - One-year outcomes from the multi-vessel subset of RESOLUTE All Comers
- Poster Abstract Session: Drug-Eluting Stents

  1:00 - 3:30 pm (Lower Level)
  - One-year results from RESOLUTE International, a large, single-arm trial evaluating the Resolute stent in 'real-world' patients with complex disease
  - PROTECT baseline clinical and angiographic characteristics of the Endeavor vs. Cypher trial
  - Long-term clinical data from the RESOLUTE First In Man study out to 4 years
  - One-year outcomes from the acute myocardial infarction subset of RESOLUTE All Comers
- Poster Abstract Session: Valvular Heart Disease: Aortic

  1:00 - 3:30 pm (Lower Level)

  - Early Effectiveness and Safety Results from the CoreValve Transcatheter Aortic Valve Australia-New Zealand Study
  - Transcatheter Aortic Valve Implantation Using the Left Subclavian Route Is Feasible and Safe
  - The Subclavian Access for TAVI with the CoreValve Bioprosthesis: Safety and Efficacy in 88 Consecutive Patients
- Drug-Eluting Stent Summit (Part 2): Next Generation DES , Bioabsorbable Stents, and Drug-Eluting Balloons(Ballroom C)
  - 11:24 am / Design specifications and preclinical results with a 'drug-filled stent'
  - 3:10 pm / The Invatec IN.PACT Falcon paclitaxel DEB: device description and clinical studies
  - 3:40 pm / Case Reviews: Use of DEB Today During Coronary PCI

Thursday, September 23

- Breakfast Meeting: Designing the Ideal Aortic Valve
  7:00 - 8:00 am (Room 150B)
- Breakfast Meeting: Making the Complex Simple: An Asia Pacific Interventional Approach to Multi Vessel Disease
  7:00 - 8:00 am (Room 144C)
- Evening Program: Establishing Safety and Efficacy for Percutaneous Aortic Valve Therapy: Where Have We Been? Where Are We Going?
  7:00 - 9:30 pm (Marriott at Metro Center Ballroom)

Friday, September 24

- Breakfast Meeting: Collaborative Approach to Cardiovascular Disease and Asia Pacific Perspective
  7:00 - 8:00 am (Room 144A)

Medtronic is also sponsoring the following scientific symposium:

New Frontiers in Cardiovascular
Medicine
Wednesday, September 22, 8:00 pm
Renaissance Hotel

Highlighted presentations from the symposium include:

- Landscape for the Future, Dr. Martin B. Leon
- The Future of Drug-Eluting Stents, Dr. Ian T. Meredith
- New Opportunities for Endovascular Therapy: DES for Erectile Dysfunction, Dr. Krishna J. Rocha-Singh
- Interventional Hypertension: The Next Big Breakthrough, Dr. Dierk Scheinert
- Transcatheter Valve Therapy: View Towards the Future, Dr. Ganesh Manoharan

In the United States, the Resolute drug-eluting stent is limited by U.S. federal law to investigational use only in an FDA-approved clinical trial, RESOLUTE US. The CoreValve System and the IN.PACT Falcon drug-eluting balloon are not available in the United States for clinical trial or commercial use or sale. All of these devices have received the CE (Conformité Européenne) mark, making them widely available outside the United States, Canada and Japan.

Medtronic is committed to advancing the treatment of cardiovascular disease through collaboration with leading clinicians, researchers and scientists worldwide.

ABOUT MEDTRONIC

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating

pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

SOURCE: Medtronic

Medtronic
Joseph McGrath, 707-591-7367
Public Relations, Vascular
or
Kathleen Janasz, 763-526-3676
Public Relations, Structural Heart
or
Jeff Warren, 763-505-2696
Investor Relations
